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In the prospective, randomized, multicenter APOMYGRE trial conducted in France,
concentration-controlled mycophenolate mofetil (MMF) dosing based on
mycophenolic acid (MPA) exposure significantly reduced the treatment failure and
acute rejection during the first posttransplantation year compared with fixed-dose
MMF. This analysis investigated the cost effectiveness of dose individualization.
METHOD:
The study included 65 patients per group (intent-to-treat population). Treatment
failure (primary efficacy endpoint) was defined as death, graft loss, acute rejection,
or MMF discontinuation because of adverse effects. Data on hospitalizations, drugs
prescribed, physicians' fees, laboratory expenses, ambulatory visits, and
transportation were retrieved. Costs were calculated from the French National
Health System perspective.
RESULTS:
The mean (95% confidence interval) total yearly cost per patient was Euro 47,477
(Euro 43,933; Euro 51,020) in the concentration-controlled group and Euro 46,783
( Euro 44,152; Euro 49,414) in the fixed-dose group (P=0.7). The observed
incremental cost-effectiveness ratio was Euro 3757 per treatment failure
(Purchasing Power Parities United States/France: $4129). Hospitalization and drug
costs accounted for approximately 50% and 25% of total costs, respectively. The
cost for MPA area under the concentration-time curve and dose calculation was
Euro 452 per patient, less than 1% of the total cost.
CONCLUSION:
In the APOMYGRE trial, therapeutic MPA monitoring using a limited sampling
strategy reduced the risk of treatment failure and acute rejection in renal allograft
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